1 Clinical manifestations and disease severity of SARS-CoV-2 infection among

2 infants in Canada

-	
4	Pierre-Philippe Piché-Renaud MD ¹ *, Luc Panetta MD ^{2,3} *, Daniel S. Farrar MPH ⁴ ,
5	Charlotte Moore-Hepburn MD ^{5,6,7} , Olivier Drouin MDCM MSc MPH ^{8,9} , Jesse Papenburg
6	MD MSc ^{10,11,12} , Marina I. Salvadori MD ^{10,13} , Melanie Laffin ¹⁴ , Fatima Kakkar [#] MD MPH ³ ,
7	Shaun K. Morris [#] MD MPH ^{1,4,7,15} for the Canadian Paediatric Surveillance Program
8	COVID-19 Study Team
9	
10	*Co-first authors
11	[#] Co-senior authors
12	
13	¹ Division of Infectious Diseases, The Hospital for Sick Children, Toronto, Canada
14	² Paediatric Emergency Department, Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Lyon, France
15	³ Division of Infectious Diseases, CHU Sainte-Justine, Montreal, Canada
16	⁴ Centre for Global Child Health, The Hospital for Sick Children, Toronto, Canada
17	⁵ Division of Paediatric Medicine, The Hospital for Sick Children, Toronto, Canada
18	⁶ Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
19	⁷ Department of Pediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
20	⁸ Division of General Pediatrics, Department of Pediatrics, CHU Sainte-Justine, Montreal, Canada
21	⁹ Department of Social and Preventive Medicine, School of Public Health, Université de Montréal, Montréal,
22	Canada
23	¹⁰ Division of Pediatric Infectious Diseases, Department of Pediatrics, The Montreal Children's Hospital,
24	McGill University Health Centre, Montreal, Quebec, Canada
25	¹¹ Division of Medical Microbiology, Department of Clinical Laboratory Medicine, McGill University Health
26	Centre, Montreal, Quebec, Canada
27	¹² Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec,
28	Canada
29	¹³ Public Health Agency of Canada, Ottawa

- 30 ¹⁴Canadian Paediatric Surveillance Program
- 31 ¹⁵Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
- 32
- 33

34 Corresponding authors:

- 35 Shaun K. Morris, Division of Infectious Diseases, The Hospital for Sick Children, 555
- 36 University Ave, Toronto, ON, M5G 1X8, Canada. Email: shaun.morris@sickkids.ca._Phone:
- 37 416-813-6625; Fax: 416-813-8404
- 38
- 39 Fatima Kakkar, Division of Infectious Diseases, Centre Hospitalier Universitaire Sainte-Justine,
- 40 3175 Chemin Cote Sainte-Catherine, Montreal, QC, H3T 1C5, Canada. Email:
- 41 fatima.kakkar@umontreal.ca. Phone: 514-345-4931 x6885
- 42
- 43 Funding Source: OD & FK are supported by a Clinical Research Scholars Award, from the
- 44 Fonds de recherche du Québec Santé. We gratefully acknowledge the financial support
- 45 received from the Public Health Agency of Canada to the Canadian Paediatric Surveillance

46 Program, in support of the COVID-19 study.

- 48 Words (Body): 3342
- 49 Words (Abstract): 339

50 Key Points

- 51 **Question:** What are the spectrum of illness, disease severity, and characteristics associated with
- 52 hospitalization in infants with SARS-CoV-2 infection?
- 53 Findings: A total of 531 cases were reported to the Canadian Paediatric Surveillance Program,
- 54 including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. In total, 20 infants
- 55 met criteria for severe disease (3.8%). Infants' characteristics associated with admission included
- age of less than one month and comorbid conditions.
- 57 Meaning: This study provides data on the spectrum of disease, severity, and characteristics
- associated with admission due to COVID-19 in infants, which informs clinical management and
- 59 public health interventions in this specific population.

60 Abstract

Importance: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical management and public health interventions.

65 **Objective:** The objective of this study was to describe the clinical manifestations, disease 66 severity, and characteristics associated with hospitalization among infants infected with the 67 initial strains of SARS-CoV-2.

Design: Prospective study of infants with SARS-CoV-2 from April 8th 2020 to May 31st 2021.

69 **Setting:** National study using the infrastructure of the Canadian Paediatric Surveillance Program,

70 reporting inpatients and outpatients seen in clinics and emergency departments.

71 **Participants:** Infants <1 year of age with microbiologically confirmed SARS-CoV-2 infection.

72 **Exposure:** Infant-level characteristics associated with hospitalization for COVID-19.

Main outcomes and Measures: Cases were classified as either: 1) Non-hospitalized patient with SARS-CoV-2 infection; 2) COVID-19-related hospitalization; or 3) non-COVID-19-related hospitalization (e.g., incidentally detected SARS-CoV-2). Case severity was defined as asymptomatic, outpatient care, mild (inpatient care), moderate or severe disease. Multivariable logistic regression was performed to identify characteristics associated with hospitalization.

Results: A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral

- 83 intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of
- hospitalization compared to infants with no comorbid conditions (aOR=4.53, 2.06-9.97), and
- 85 infants <1 month had higher odds of hospitalization then infants aged 1-3 months (aOR=3.78,
- 1.97-7.26). In total, 20 infants (3.8%) met criteria for severe disease.
- 87 Conclusions and Relevance: We describe one of the largest cohorts of infants with SARS-CoV-
- 2 infection. Overall, severe COVID-19 in this age group is uncommon with most infants having
- 89 mild disease. Comorbid conditions and younger age were associated with COVID-19-related
- 90 hospitalization amongst infants.

91 BACKGROUND

Approximately two years into the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pandemic, the clinical presentation of Coronavirus Disease 2019 (COVID-19) and risk factors
for disease severity among adults and older children have now been well documented.¹⁻⁵
However, there is still an important knowledge gap regarding disease manifestation and risk
factors for severe disease in newborns and infants infected with SARS-CoV-2.

97 To date, there have been few published studies describing outcomes in infants with SARS-CoV-2 infection, with conflicting data on young age as a risk factor for severe disease.⁶⁻⁸ Some studies 98 have reported that infants are more at risk of severe disease than older children, while others 99 have shown similar risk across pediatric age groups. More specifically, some authors have 100 suggested that neonates (<28 days of life)^{9,10} and infants (<1 year-old) may be at higher risk of 101 severe disease than older children.^{1,11-15} However, most of these studies have not included data 102 103 on non-hospitalized and asymptomatic infants with SARS-CoV-2 infection and as such, the complete disease spectrum in this age group remains unknown. 104

A thorough understanding of COVID-19 in infants, including characteristics that are associated with hospitalization, would inform management and preventive interventions for this specific age group, including future vaccination strategies.^{16,17} The objective of this study was to describe the clinical manifestations and disease severity among infants with microbiologically confirmed SARS-CoV-2 infection reported to the Canadian Paediatric Surveillance Program (CPSP) between April 2020 and May 2021, and to explore infant characteristics that may be associated with hospitalization for COVID-19.

112

114 METHODS

115 Study design and setting

The CPSP is a national public health surveillance platform designed to collect information on 116 117 rare childhood disorders, and is administered jointly by the Canadian Paediatric Society and the Public Health Agency of Canada (PHAC).¹⁸ Using weekly active surveillance for incident cases 118 and online case reporting forms, the CPSP COVID-19 study gathered information through its 119 network of more than 2,800 paediatricians and paediatric subspecialists across Canada.^{18,19} 120 121 Beginning on April 8, 2020, CPSP participants were asked to report on three different groups: (1) children admitted to hospital with acute SARS-CoV-2 infection, (2) non-hospitalized children 122 with acute COVID-19 AND at least one chronic comorbid condition or less than one year of age 123 and (3) children with multisystem inflammatory syndrome in children (MIS-C) associated with 124 COVID-19.²⁰ The detailed study protocol including case definitions and case report form for all 125 126 COVID-19-related CPSP studies are available at: https://www.cpsp.cps.ca/surveillance/study-127 etude/covid-19.

128 This particular study was designed to analyze patient-level data on infants less than one year of age who were infected with SARS-CoV-2. Data on demographic characteristics, epidemiology 129 of cases, clinical and laboratory features, treatments, and outcomes were collected. Clinical 130 syndromes were reported directly from clinicians (e.g., pneumonia, bronchiolitis). A clinical 131 syndrome of upper respiratory tract infection (URTI) was constructed post hoc when symptoms 132 of coryza or rhinorrhea were reported. Cases of multisystem inflammatory syndrome in children 133 (MIS-C) were not included in this study. To optimize case capture, this study also included 134 additional active case finding from three large pediatric centers: The Hospital for Sick Children 135 136 (HSC, Toronto, Ontario), CHU Sainte-Justine (HSJ, Montréal, Québec) and the Montreal

137 Children's Hospital (MCH, Montréal, Québec). For these three centers, weekly extraction of 138 infection prevention and control lists were performed using the hospital Electronic Medical 139 Records (EMR) systems, which includes all children who had a positive SARS-CoV-2 PCR from 140 the hospital laboratory, and all children who tested positive in another center and subsequently 141 transferred for hospital admission. Of note, these three centers are located in the two most 142 populous provinces that had the most COVID-19 cases in Canada during the study time frame 143 (Québec and Ontario).²¹

144

145 **Study definitions**

Cases were classified into one of the following mutually exclusive categories: 1) Non-146 hospitalized infants who tested positive for SARS-CoV-2; 2) COVID-19-related hospitalization: 147 148 an infant hospitalized due to clinical features directly related to the SARS-CoV-2 infection; 3) 149 Non-COVID-19-related hospitalization (e.g., incidentally detected SARS-CoV-2, isolation, or 150 social reasons). For each hospitalized infant, at least two study team members (PPPR, LP, SKM, 151 or FK) reviewed all available clinical and diagnostic information on the case report form to ensure the accuracy of the physician-reported case classification. Any discrepancies in the 152 153 assignment of category of illness were resolved by reporting physician follow-up and/or 154 consensus discussion by the study team.

A COVID-19 disease severity classification was adapted to the CPSP case reporting form from the World Health Organization COVID-19 Clinical Characterisation and Management Working Group scale²², and was defined as such: 1) Asymptomatic: Patients reported to have no clinical signs or symptoms of COVID-19; 2) Outpatient care: any reported symptoms of COVID-19 and no admission required (including from pediatric COVID-19 clinics and pediatric emergency

160 department); 3) Mild disease (inpatient): Admitted with symptoms of COVID-19, but no targeted 161 treatment against COVID-19 required and no respiratory support required; 4) Moderate disease: 162 Admitted with symptoms of COVID-19 and received low-flow oxygen, had oxygen therapy 163 above home baseline needs or received targeted treatment against COVID-19 including remdesivir or steroids; 5) Severe disease: Infants who experienced acute respiratory distress 164 syndrome (ARDS) or severe neurological symptoms (seizures or coma), or who required 165 166 intensive care unit (ICU) admission, ventilation (including high-flow nasal cannula, non-invasive 167 ventilation, conventional mechanical ventilation, high-frequency oscillatory ventilation) or 168 vasopressors. The detailed criteria for severity classification can be found in the supplementary 169 material (eTable 1). Cases were included from the first wave (occurred between March and June 2020), the second wave (September 2020 to January 2021) and the third wave (between March 170 171 and May 2021) of the pandemic in Canada. With the emergence of SARS-CoV-2 variants of 172 concerns (VOC) in Canada starting on December 26, 2020, the study was amended to gather data 173 on SARS-CoV-2 mutation testing (N501Y and E484K) for detection of the Alpha (B.1.1.7), Beta 174 (B.1.351) and Gamma (P.1) lineages from the three hospitals that have performed active case finding (HSC, HSJ and MCH), including on previously reported cases. Cases occurring before 175 December 26, 2020 were assumed to be 'not a confirmed VOC'. 176

Infant age was categorized as neonates (<1 month; 1-28 days old), 1–3-month-old infants (29-91 days old), 4–6-month-old infants (92-182 days old) and 7–12-month-old infants (183-365 days old). These age categories were based on the significant differences in the routine management of well-appearing febrile infants aged <1 months and older infants.²³ Amongst patients aged older than 3 months, a category was created for infants aged more than 6 months of age since this population has been included in clinical trials on COVID-19 vaccination and thus have

specific considerations. Prematurity was defined as gestational of less than 37 weeks, andpreterm infants were included based on their chronologic age.

185

186 Statistical Analysis

Demographic characteristics were analyzed using frequencies, percentages, medians, and 187 interquartile ranges. Differences in age groups and severity categories were assessed using 188 Fisher's exact tests, χ^2 tests, and Kruskal-Wallis tests. A statistical significance threshold of 189 α =0.05 was used for all comparisons. Multivariable logistic regression was performed to identify 190 191 infant characteristics associated with hospitalization due to COVID-19, after excluding infants 192 hospitalized with incidental SARS-CoV-2 infection. Variables for the primary adjusted model were selected a priori on the basis of literature review and available elements on the case report 193 194 form. Given a smaller available sample size for the post hoc VOC model, the variable with the 195 lowest pairwise correlation with hospitalization (i.e., infant sex) was excluded while VOC status was forced into the adjusted model. Odds ratios (OR) and 95% confidence intervals (CI) were 196 calculated. Unadjusted comparisons between infants hospitalized because of COVID-19 with 197 severe and non-severe disease were performed using a Wilcoxon rank-sum test and chi-square 198 199 test (excluding cases that were admitted for reasons other than COVID-19). Logistic regression 200 to identify factors associated with disease severity could not be performed due to the small 201 number of infants with severe disease. Sensitivity analyses were conducted using only the cases 202 from the three centres that systematically screened for inclusion all infants who tested positive 203 for SARS-CoV-2 (HSC, HSJ and MCH). Analyses were conducted using Stata 17 (StataCorp, College Station, TX). Due to CPSP privacy policies, frequencies between one and four were 204 205 masked and reported as '<5'. In some instances, the results of subgroup analyses were presented 206 as ranges to prevent back-calculation of frequencies <5.

207

208 Ethical approval

The CPSP operates under the legal authority derived from Section 4 of the Department of Health Act and Section 3 of the Public Health Agency of Canada Act. Ethics approval was obtained from the Public Health Agency of Canada and Health Canada Research Ethics Board (REB 2020-002P), The Hospital for Sick Children (REB 1000070001) and the Institutional Review Board of the Centre Hospitalier Universitaire Sainte-Justine (IRB MP-21-2021-2901) as well as at individual sites, as required by local policies. In Québec, the study was conducted as a multicenter study, with clinical data collected by the study co-investigators.

216

217 **RESULTS**

218 **Patient demographics**

From April 8th, 2020 to May 31st, 2021 a total of 531 infants aged <1 year old were reported to 219 CPSP, including 199 (37.5%) hospitalized and 332 (62.5%) non-hospitalized infants (Figure 1). 220 221 Cases were reported from all provinces with the majority from Québec and Ontario (Figure 2). Full data capture was not possible for Alberta because of delays in securing the appropriate data-222 transfer agreements. Eighty-one infants (15.4%) were neonates (≤28 days old), of whom 13 were 223 224 \leq 7 days old and 67 between 8 to 28 days old (one infant could not be categorized). Most infants 225 had a known close contact with a confirmed case of SARS-CoV-2 infection (n=302, 58.5%), with either their parents (n=247; 79.2%), siblings (n=46, 14.7%), other relatives (n=51, 16.4%), 226 or non-family members (n=13, 4.2%). Other infant characteristics are shown in Table 1. 227

228

230 Clinical characteristics

231 From all reported infants, 66 (12.4%) were asymptomatic from SARS-CoV-2 infection (Table 2). 232 Among symptomatic infants, the most common presenting symptoms were fever (n=353, 233 66.5%), coryza (n=250, 47.1%), cough (n=198, 37.3%) and decreased oral intake (n=133, 25.0%) (Table 2). The most common clinical syndromes were URTI (n=321, 60.5%), followed 234 by gastrointestinal syndrome (161, 30.3%). Few infants had bronchiolitis (n=20, 3.8%) or 235 236 pneumonia (n=14, 2.6%). A total of 59 infants (11.1%) had at least one comorbidity, including 237 congenital heart disease (n=20, 3.8%), neurologic/neurodevelopmental disease (n=19, 3.6%) and chronic lung disease (n=10, 1.9%). Fourteen infants (2.6%) had more than one co-morbidity. 238 Most infants were born at term (n=445, 88.8%), with 29 (5.8%) born prematurely between 34 239 and 36 weeks of gestation and 27 infants (5.4%) born before 34 weeks of gestation (Table 1). 240

241

242 Hospitalization for COVID-19

Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-243 244 related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19 (Table 1). Neonates (<1 month) were more likely to be hospitalized for COVID-19, with an adjusted odds 245 ratio (aOR) of 3.78 (95% CI, 1.97 – 7.26) when compared with infants aged 1-3 months. Infants 246 247 aged 4-6 months and 7-12 months were less likely to be admitted than infants aged 1-3 months with an aOR of 0.24 (95% CI, 0.12 - 0.47) and aOR of 0.13 (95% CI, 0.06 - 0.25), respectively 248 (Table 3). The median age for infants managed as outpatients was 160 days (Interquartile range 249 250 [IQR], 73 – 263 days), and the median age for infants admitted for COVID-19-related illness 251 was 37 days (IQR, 22 – 115 days, p<0.001). Odds ratios for COVID-19 admission by continuous 252 infant age, with infants at 100 days of age as the reference point are reported in the

253 Supplementary eFigure 1. Infants born before 34 weeks of gestation were at increased odds of 254 being hospitalized for COVID-19 compared to infants born at term (aOR, 3.54; 95% CI, 1.19 – 255 10.46). Infants with ≥ 1 comorbid condition(s) were also at increased odds of hospitalization for 256 COVID-19 compared to infants with no known comorbid conditions (aOR, 4.53; 95% CI, 2.06 – 257 9.97). Sensitivity analyses were conducted to confirm results among the two Montreal and the Toronto centres with systematic case reporting. While associations between hospitalization, 258 259 comorbidities, and young age remained consistent, these analyses showed a higher proportion of 260 non-hospitalized infants (n=275/374, 73.5%) and the association between preterm birth before 34 261 weeks of gestation and hospital admission was not statistically significant (aOR 2.21; 95% CI, 0.55-8.95, Supplementary eTable 2 and eTable 3). In these analyses, similarly to the analyses 262 performed on the full dataset, comorbidities and young age were also associated with admission 263 264 for COVID-19 (Table 4 and Table 5).

265

266 Severe COVID-19 disease amongst infants hospitalized for COVID-19

267 Amongst infants hospitalized because of COVID-19-related illness, 111 of 141 infants (78.7%) had mild disease, 10 (7.1%) had moderate disease and 20 (14.2%) had severe disease. A 268 269 comparison of disease severity classification of our cases using the objective CPSP criteria, 270 versus the Dong severity criteria is shown in Supplementary eTable 7. Fewer than five infants 271 with COVID-19 died. Fourteen infants (9.9%) were admitted to the ICU, with <5 infants requiring non-invasive ventilation and 5 infants requiring mechanical ventilation (Table 2). A 272 273 higher proportion of neonates aged <1 month (26.5%) admitted for COVID-19 required 274 respiratory support (oxygen, non-invasive ventilation and mechanical ventilation) compared to 275 infants aged 1-12 months (11.0%, p=0.02) (Supplementary eTable 5). The median age of

inpatients with severe disease was 19 days (IQR 10–83) compared to 42 days (IQR 23–94)
among inpatients with non-severe disease (p=0.03). Inpatients with severe disease were more
likely to be premature (<37 weeks' gestation; 7/20 [35.0%]) than inpatients with non-severe
disease (11/119 with known prematurity status [9.2%]; p=0.005).

280

281 **Treatment and management**

282 Almost all infants managed as outpatients (314 of 332, 94.6%) did not receive any treatment, 283 whereas 61 (43.3%) infants hospitalized for COVID-19 did not receive any treatment (p < 0.001) 284 (Supplementary eTable 6). Antibiotics were the most frequent treatment modality (94/473, 285 19.9%), and neonates aged <1 month received antibiotics more frequently (35/69, 47.7%) than infants aged 1-3 months (34/138, 24.6%) and infants aged 4-12 months (25/262, 9.5%, p-<0.001). 286 287 Few infants received systemic corticosteroids (11/473, 2.3%), including seven infants who received steroids for a non-COVID-19 related reason (for example, laryngitis). Less than five 288 289 infants (<1.1%) received remdesivir, and no patients were treated with biologic response 290 modifying drugs, anticoagulation (e.g. prophylactic, therapeutic, mechanical), or chloroquines 291 (e.g. chloroquine, hydroxychloroquine).

292

293 SARS-CoV-2 variants of concern

From centers contributing SARS-CoV-2 lineage data (HSC, HSJ and MCH), 60 infants screened positive for VOC, all of whom tested positive on or after February 24, 2021. This included 39 infants with the Alpha VOC and 21 infants with another VOC (including Beta, Gamma or unspecified N501Y+ VOC) (Supplementary eTable 3). In our VOC adjusted model, no SARS-CoV-2 lineage was associated with an increased odds of hospitalization in infants (Table 3). The

aOR of hospitalization for VOC compared to the SARS-CoV-2 ancestor strain was 0.63 (95% CI, 0.27 - 1.48). The phase of the pandemic (first, second or third wave) was not associated with an increased odds of hospitalization in infants.

302

303 **DISCUSSION**

This study describes the clinical manifestations and severity of disease in infants less than one year of age with microbiologically-confirmed SARS-CoV-2 infection in Canada in outpatient and hospital settings prior to May 2021. While previous studies on COVID-19 in infants have focused only on hospitalized patients with symptomatic disease and may therefore have overestimated the severity of COVID-19 in this age group, this study provides a more complete description of the possible range of presentations of infants with SARS-CoV-2 infection by including a subset of infants seen in outpatient settings.^{9,24,25}

Similar to the results of previous studies, including meta-analyses and systematic reviews on 311 pediatric COVID-19, we report that severe COVID-19 is uncommon in infants, especially when 312 compared to adults and adolescents.²⁶⁻²⁹ It is thought that the difference in severity from SARS-313 CoV-2 infection between age groups relates to distinct immune responses and expression in 314 receptors of angiotensin-converting enzyme-2 (ACE-2) in younger children.³⁰ However, 315 316 consistent with previous studies, we found that amongst infants, neonates aged <1 month were at increased risk for hospitalization.^{9,10,13,15,31} Although a low threshold for admission in infants 317 aged less than 6 to 12 weeks who present with fever may impact hospitalization rates, a larger 318 proportion of neonates aged <1 month admitted for COVID-19 have also required respiratory 319 support compared to older infants, including 5 who required mechanical ventilation.²³ The 320 321 increased severity of SARS-CoV-2 infection seen in young neonates may relate to their small

322 airways and reduced innate immune responses, especially in the absence of passive immunity from maternal antibodies against SARS-CoV-2.^{32,33} Several studies and reports have 323 demonstrated successful placental transmission of SARS-CoV-2 antibodies after maternal 324 vaccination.³⁴⁻³⁶ Thus, in the absence of any COVID-19 vaccine approved for use in young 325 326 infants, an important strategy to protect neonates against severe SARS-CoV-2 may be through maternal immunization. With multiple jurisdictions reporting lower COVID-19 vaccine coverage 327 328 in pregnant women compared to the general population, efforts should be made to optimize their acceptance and uptake of COVID-19 vaccines.^{37,38} 329

Our results also suggest that preterm infants (<37 weeks of gestation) may be at higher risk of 330 severe COVID-19 compared to term infants. While a multivariable analysis revealed higher odds 331 of admission in preterm infants, this result was not consistent in our sensitivity analysis on the 332 333 data from centres with systematic case reporting. To date, there have been very few data 334 describing the spectrum of COVID-19 manifestations in infants who are born prematurely. Some case reports have described severe disease requiring intubation in premature neonates infected 335 with SARS-CoV-2, whereas others have described an overall mild course.³⁹⁻⁴³ Thus, further 336 research on the spectrum of illness of SARS-CoV-2 infection in this population is needed. 337

The emergence of new SARS-CoV-2 lineages have raised concerns for differences in susceptibility and virulence in the pediatric population.⁴⁴ In Ontario and Québec, the provinces from which most of our study subjects have been reported, the third wave of the pandemic that occurred from March to May 2021 was mostly comprised of the Alpha variant.⁴⁵ Reassuringly, we did not find any significant difference in the proportion of infants admitted for COVID-19 during the third wave of the pandemic, or between SARS-CoV-2 lineages. However, we have limited data on Delta (B.1.617) variant, and no data on Omicron (B.1.1.529) variant. The first

345 cases of the Delta VOC were identified in Québec on April 21, 2021 by using whole genome 346 sequencing (WGS), as the variant is negative for the detection of N501Y and E484K mutations (widely used for VOC screening).¹⁶ Since we were unable to obtain data on WGS in our study, 347 348 SARS-CoV-2 isolates that were negative for both N501Y and E484K mutations from April 21st to May 31st may have been Delta VOC that were misclassified as wild-type SARS-CoV-2. All 349 350 data preceded the Omicron wave of the pandemic. Further data on possible increased 351 susceptibility and severe outcomes in infants secondary to the Delta and Omicron VOC will be 352 needed.

353 This study is also limited by the voluntary nature of reporting in the CPSP system, and therefore, we have not captured data on every infant who tested positive for SARS-CoV-2 in Canada, nor 354 infants who were infected but for whom parents did not seek health care. Under-reporting of 355 356 outpatient cases may have also caused an information bias in comparison between hospitalized 357 and non-hospitalized patients, likely leading to over-estimation of the proportion of infants who 358 require hospitalization for COVID-19. For cases diagnosed in the first days of life, we were also 359 unable to differentiate SARS-CoV-2 infection acquired congenitally versus postnatally, and the possible impact of the method of transmission on disease severity in infants. Although we 360 described the distribution of cases by population group, we are unable to draw any conclusions 361 because this variable was reported by physicians, and not by families. Lastly, we were unable to 362 363 obtain information on the vaccination status or prior infection of the infants' mothers.

364

365 CONCLUSION

366 Our study has shown that SARS-CoV-2 infection prior to the Omicron wave generally causes 367 mild illness in infants, but that comorbid conditions and younger age were associated with

COVID-19-related hospitalization. Thorough understanding of the spectrum of disease and characteristics associated with severe disease in young infants may inform the clinical management and public health interventions targeted to this population. In the absence of available COVID-19 vaccines in infants, increasing acceptance and uptake of COVID-19 vaccines in pregnant women is likely to be an important strategy to protect young infants against SARS-CoV-2 infection.

374

375

376 ACKNOWLEDGEMENTS

The authors wish to thank the paediatricians, paediatric sub-specialists, and health professionals who voluntarily respond to CPSP surveys. We also wish to thank Dr. Jim Kellner, MD, MSc for his guidance and support, as well as the members and leadership of the Paediatric Inpatient Research Network (PIRN) for cases reported. We thank Lorraine Piché for her assistance at the Montreal Children's Hospital site. Lastly, the authors also wish to thank members of the CPSP Scientific Steering Committee who oversee the program and the managers and staff of the CPSP who implement the program.

384

386 COMPLETE LIST OF CPSP AUTHORS

	Division of General Pediatrics, Department of Pediatrics, CHU Sainte-Justine, Montréal, Que.				
Olivier Drouin	Department of Social and Preventive Medicine, School of Public Health, Université de Montréal, Montréal, Que.				
Charlotte Moore-Hepburn	Division of Paediatric Medicine, The Hospital for Sick Children, Toronto, Ont.				
Daniel S. Farrar	Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ont.				
Krista Paora	Department of Pediatrics, University of Saskatchewan, Saskatoon, Sask.				
Krista Baerg	Jim Pattison Children's Hospital, Saskatchewan Health Authority, Saskatoon, Sask.				
Kevin Chan	Department of Children's and Women's Health, Trillium Health Partners, Mississauga, Ont.				
	Department of Pediatrics, University of Toronto, Toronto, Ont.				
Claude Cyr	Service de Soins Intensifs Pédiatriques, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Que.				
	Faculté de Médecine, Université de Sherbrooke, Sherbrooke, Que.				
Elizabeth J. Donner	Division of Neurology, The Hospital for Sick Children, University of Toronto, Toronto, Ont.				
Joanne E. Embree	Department of Paediatrics and Child Health, University of Manitoba, Winnipeg, Man.				
Joanne E. Embree	Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Man.				
Catherine Farrell	Division of Pediatric Intensive Care, Department of Pediatrics, CHU Sainte-Justine, Montréal, Que.				
Sarah Forgie	Division of Infectious Diseases, Department of Pediatrics, University of Alberta, Edmonton, Alta.				
	Stollery Children's Hospital, Edmonton, Alta.				
Ryan Giroux	Division of Paediatric Medicine, The Hospital for Sick Children, Toronto, Ont.				
Kristopher T. Kang	Department of Pediatrics, University of British Columbia, Vancouver, BC.				
Melanie King	Canadian Paediatric Surveillance Program, Canadian Paediatric Society, Ottawa				
Melanie Laffin	Canadian Paediatric Surveillance Program, Canadian Paediatric Society, Ottawa				
	Division of Paediatric Medicine, The Hospital for Sick Children, Toronto, Ont.				
Julia Orkin	Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ont.				

Josso Doponhurg	Division of Pediatric Infectious Diseases, Department of Pediatrics, Montreal Children's Hospital, Montréal, Que.				
Jesse Papenburg	Division of Microbiology, Department of Clinical Laboratory Medicine, McGill University Health Centre, Montréal, Que.				
Catherine M. Pound	Division of General Pediatrics, Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ont.				
Victoria E. Price	Division of Pediatric Hematology/Oncology, Department of Pediatrics, Dalhousie University, Halifax, NS.				
	Department of Pediatrics, University of Saskatchewan, Saskatoon, Sask.				
Rupena Purewal	Division of Pediatric Infectious Diseases, Jim Pattison Children's Hospital, Saskatchewan Health Authority, Saskatoon, Sask.				
Manish Sadarangani	Department of Pediatrics, University of British Columbia, Vancouver, BC.				
Manish Sadarangani	Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC.				
	Public Health Agency of Canada, Ottawa				
Marina I. Salvadori	Division of Pediatric Infectious Diseases, Department of				
	Pediatrics, Montreal Children's Hospital, Montréal, Que.				
Karina A. Top	Department of Pediatrics, Dalhousie University, Halifax, NS.				
lsabelle Viel-Thériault	Division of Infectious Diseases, Department of Pediatrics, CHU de Québec-Université Laval, Québec City, Que.				
Fatima Kakkar	Division of Infectious Diseases, CHU Sainte-Justine, Montréal, Que.				
	Division of Infectious Diseases, The Hospital for Sick Children, Toronto, Ont.				
	Centre for Global Child Health, The Hospital for Sick Children,				
	Toronto, Ont				
Shaun K. Morris	Department of Pediatrics, Temerty Faculty of Medicine,				
	University of Toronto, Toronto, Canada				
	Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Ont.				

Conflict of interest statement: JP reports grants to his institution from MedImmune, Merck, 390 391 Sanofi Pasteur and AbbVie, and speaker fees from AbbVie and AstraZeneca, all outside of the submitted work. MS is supported via salary awards from the BC Children's Hospital Foundation, 392 393 the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for 394 Health Research. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Segirus, Symvivo and VBI Vaccines. All funds have been paid to his 395 institute, and he has not received any personal payments. PPPR has been co-investigator on an 396 397 investigator-led project funded by Pfizer that is unrelated to this study. RP is a consultant for Verity Pharmaceuticals. SKM is co-principal investigator on an investigator-led grant from 398 Pfizer, has served on an ad-hoc advisory boards for Pfizer and Sanofi Pasteur, and has received 399 speaker fees from GlaxoSmithKline, all unrelated to this study. 400

401 Figure 1: Flow chart of cases reported to the CPSP COVID-19 study until May 31, 2021.





Figure 2a. Cases of SARS-CoV-2 infection among infants reported to the CPSP, by Canadian region*








- 409 Saskatchewan, and Yukon. Atlantic Canada includes Newfoundland & Labrador, New Brunswick, Nova Scotia, and
- 410 Prince Edward Island.
- 411
- 412 Figure 2b. Cases of SARS-CoV-2 infection among infants reported to the CPSP, by

413 admission status



			Inpatie		
Characteristics	All Infants	Outpatients	Not COVID-19 related	COVID-19 related	P value
Total cases reported, N	531	332	58	141	
Infant age (days), median (IQR) ¹	112 (43–240)	158 (75–263)	138 (35–263)	37 (20–87)	<0.001
Infant age category, n (%) ¹					<0.001
<1 month	81 (15.4)	20 (6.1)	12 (21.4)	49 (35.0)	
1–3 months	151 (28.8)	82 (24.9)	13 (23.2)	56 (40.0)	
4–6 months	112 (21.3)	81 (24.6)	13 (23.2)	18 (12.9)	
7–12 months	181 (34.5)	146 (44.4)	18 (32.1)	17 (12.1)	
Infant sex, n (%)					0.45
Female	232 (43.7)	152 (45.8)	23 (39.7)	57 (40.4)	
Male	299 (56.3)	180 (54.2)	35 (60.3)	84 (59.6)	
Population group of infant, n (%) ²					
White	90 (16.9)	32 (9.6)	13 (22.4)	45 (31.9)	<0.001
South Asian	63 (11.9)	38 (11.4)	6 (10.3)	19 (13.5)	0.77
Arab/West Asian	41 (7.7)	15 (4.5)	5 (8.6)	21 (14.9)	<0.001
Black	40 (7.5)	19 (5.7)	8 (13.8)	13 (9.2)	0.06
East/Southeast Asian	25 (4.7)	18 (5.4)	<5 (<8.6)	<5 (<3.5)	0.48
		- ()	6–9		
Indigenous	16 (3.0)	<5 (<1.5)	(10.3–15.5)	5-8 (3.5-5.7)	<0.001
Other		9–12 (2.7–3.6)	<5 (<8.6)	<5 (<3.5)	0.57
Unknown	254 (47.8)	204 (61.4)	15 (25.9)	35 (24.8)	<0.001
Region of residence, n (%) ³					
Québec	251 (47.3)	162 (48.8)	21 (36.2)	68 (48.2)	
Ontario	233 (43.9)	164 (49.4)	24 (41.4)	45 (31.9)	
West/North	47 (8.9)	6 (1.8)	13 (22.4)	28 (19.9)	
Atlantic	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	
Gestational age at birth, n (%) ⁴					<0.001
Term (≥37 weeks')	445 (88.8)	284 (93.1)	40 (70.2)	121 (87.1)	
Late preterm (34–<37 weeks')	29 (5.8)	12 (3.9)	9 (15.8)	8 (5.8)	
Moderate/very preterm (<34	27 (5.4)	9 (3.0)	8 (14.0)	10 (7.2)	
weeks')	27 (5.4) 34.0	9 (3.0) 34.0	8 (14.0) 34.6	32.9	
Median (IQR) weeks at birth 5	(31.4–35.5)	(32.4–35.7)	(30.0–35.0)	(29.0–35.4)	0.48
Any comorbid condition, n (%)	59 (11.1)	23 (6.9)	18 (31.0)	18 (12.8)	<0.001
Congenital heart disease	20 (3.8)	9 (2.7)	6 (10.3)	5 (3.5)	0.03
Neurologic/neurodevelopmental	19 (3.6)	6–9 (1.8–2.7)	8-11 (13.8–19.0)	<5 (<3.5)	<0.001
Chronic lung disease	10 (1.9)	<5 (<1.5)	<5 (<8.6)	5 (3.6)	0.007

325 (97.9)

17 (5.1)

25 (4.7)

47 (8.9)

49 (84.5)

18 (31.0)

Other⁶

Any co-infections, $n(\%)^7$

415 Table 1. Characteristics of infants with SARS-CoV-2 infection in Canada.

< 0.001

132 (93.6)

12 (8.5)

COVID-19 exposure, n (%)

Known close contact with confirmed SARS-CoV-2 infection	312 (58.8)	187 (56.3)	28 (48.3)	97 (68.8)	0.01
Nosocomial infection	9 (1.7)	0 (0.0)	5–8 (8.6–13.8)	<5 (<3.5)	<0.001

¹Continuous age not available for 13 infants (8 outpatients, 2 non-COVID admissions, 3 COVID admissions); categorical age not available for 6 infants (3 outpatients, 2 non-COVID admissions, 1 COVID admission).

²Physicians could report multiple population groups. East/Southeast Asian includes Chinese, Filipino, Japanese, Korean, and Southeast Asian. Indigenous includes First Nations, Inuit, and Métis.

³Overall, West/North includes cases from Manitoba (n=16), Alberta (n=14), Saskatchewan (n=10), and either Northwest Territories, Nunavut, or British Columbia (n=7). Zero cases were reported from Yukon. Atlantic includes New Brunswick, Newfoundland and Labrador, Nova Scotia, and Prince Edward Island.

⁴Gestational age category not known for 30 infants (27 outpatients, 1 non-COVID admission, 2 COVID admissions).

⁵Among preterm-born infants only (i.e. <37 weeks' gestation).

⁶Includes 8 gastrointestinal/liver disease, 8 sickle cell/other hematologic disorder, 6 immunosuppressing conditions, 5 renal disease, and <5 not otherwise specified. Multiple conditions may have been reported.

⁷Includes 19 urinary tract infections, 7 invasive bacterial infections, 6 concomittant viral infections, 5 acute otitis media/bacterial pneumonia, and <5 each of candidiasis, laryngitis/pharyngitis, other benign bacterial infections, and skin and soft tissue infections. 416

._.

417

Table 2. Symptoms, laboratory findings, and clinical syndromes of infants with SARS CoV-2 infection

			Inpatients		
Clinical features	All Cases Outpatients		Not COVID-19 related	COVID-19 related	
Total cases reported, N	531	332	58	141	
COVID-19 severity, n (%)					
Asymptomatic	66 (12.4)	22 (6.6)	44 (75.9)		
Outpatient care	310 (58.4)	310 (93.4)			
Inpatient care, mild	125 (23.5)		14 (24.1)	111 (78.7)	
Inpatient care, moderate	10 (1.9)			10 (7.1)	
Inpatient care, severe	20 (3.8)			20 (14.2	
Symptoms and signs, n (%)					
Fever	353 (66.5)	232 (69.9)	14 (24.1)	107 (75.9	
Coryza	250 (47.1)	188 (56.6)	6 (10.3)	56 (39.7	
Cough	198 (37.3)	143–146 (43.1–44.0)	<5 (<8.6)	50–53 (35.5–37.6	
Decreased oral intake	133 (25.0)	77 (23.2)	6 (10.3)	50 (35.5	
Vomiting	93 (17.5)	57 (17.2)	10 (17.2)	26 (18.4	
Diarrhea	78 (14.7)	51–54 (15.4–16.3)	<5 (<8.6)	22–25 (15.6–17.7	
Respiratory distress	55 (10.4)	17–20 (5.1–6.0)	<5 (<8.6)	32–35 (22.7–24.8	
Lethargy	53 (10.0)	19 (5.7)	7 (12.1)	27 (19.1	
Rash	49 (9.2)	35–38 (10.5–11.4)	<5 (<8.6)	10–13 (7.1–9.2	
Irrita bility ¹	46 (8.7)	29–32 (8.7–9.6)	<5 (<8.6)	12–15 (8.5–10.6	
Sneezing	44 (8.3)	31 (9.3)	0 (0.0)	13 (9.2	
Tachycardia ¹	27 (5.1)	21 (6.3)	<5 (<8.6)	<5 (<3.5	
Conjunctivitis	13 (2.4)	6 (1.8)	0 (0.0)	7 (5.0	
Laboratory findings, n (%)	(,	- ()	- ()	. (
Neutropenia	34 (6.4)	9–12 (2.7–3.6)	<5 (<8.6)	19–22 (13.5–15.6	
Lymphopenia	22 (4.1)	7 (2.1)	0 (0.0)	15 (10.6	
Thrombocytosis	14 (2.6)	5-8 (1.5-2.4)	<5 (<8.6)	5–8 (3.5–5.7	
, Anemia	8 (1.5)	0 (0.0)	<5 (<8.6)	5–7 (3.5–5.0	
Clinical syndromes, n (%)				,	
Upper respiratory tract infection	321 (60.5)	231 (69.6)	8 (13.8)	82 (58.2	
Gastrointestinal	161 (30.3)	103 (31.0)	13 (22.4)	45 (31.9	
Bronchiolitis	20 (3.8)	6 (1.8)	0 (0.0)	14 (9.9	
Pneumonia	14 (2.6)	0 (0.0)	<5 (<8.6)	10-13 (7.1-9.2	
Coagulopathy	7 (1.3)	0 (0.0)	<5 (<8.6)	5–6 (3.5–4.3	
Seizure(s)	7 (1.3)	0 (0.0)	<5 (<8.6)	<5 (<3.5	
Hepatitis	5 (0.9)	<5 (<1.5)	0 (0.0)	<5 (<3.5	
Acute respiratory distress syndrome	<5 (<0.9)	0 (0.0)	0 (0.0)	<5 (<3.5	
Cardiac dysfunction	<5 (<0.9)	0 (0.0)	<5 (<8.6)	<5 (<3.5	
,	32/132	<5/28	5-8/19	21-24/85	
Abnormal CXR, n (%) / cases with imaging	(24.2)	(<17.9)	(26.3–42.1)	(24.7–28.2)	

Any respiratory support required, n (%)		 	23 (16.3)
Low-flow oxygen		 	15 (10.6)
High-flow nasal cannula		 	5 (3.5)
Non-invasive ventilation		 	<5 (<3.5)
Mechanical ventilation ²		 	5 (3.5)
Vasopressors		 	0 (0.0)
Admitted to ICU, n (%)		 	14 (9.9)
Infant died, n (%)	<5 (<0.9)	 	<5 (<3.5)

¹Symptoms included as write-in notes only and may therefore be underrepresented.

²Includes conventional mechanical and high-frequency oscillatory ventilation.

	Crude model		Adjusted model ¹		VOC adjusted model ²	
Characteristics, n (% _{row})	OR (95% CI)	P value	aOR (95% CI)	P value	aOR (95% CI)	P value
Infant age						
0–<1 month	3.59 (1.93–6.68)	<0.001	3.78 (1.97–7.26)	<0.001	3.47 (1.42-8.52)	0.007
1–3 months	1 [Reference]	NA	1 [Reference]	NA	1 [Reference]	NA
4–6 months	0.33 (0.18–0.60)	<0.001	0.24 (0.12-0.47)	<0.001	0.30 (0.12–0.78)	0.01
7–12 months	0.17 (0.09–0.31)	<0.001	0.13 (0.06–0.25)	<0.001	0.12 (0.05–0.34)	<0.001
Infant sex						
Female	1 [Reference]	NA	1 [Reference]	NA		
Male	1.24 (0.83-1.86)	0.28	1.14 (0.71-1.84)	0.58		
Gestational age at birth						
Term (≥37 weeks')	1 [Reference]	NA	1[Reference]	NA		
Late preterm (34—<37 weeks')	1.56 (0.62–3.92)	0.34	1.25 (0.42–3.72)	0.69		
Moderate/very preterm (<34 weeks')	2.61 (1.03-6.58)	0.04	3.54 (1.19–10.46)	0.02		
Comorbid conditions						
None/Unknown	1 [Reference]	NA	1 [Reference]	NA	1 [Reference]	NA
≥1 comorbid condition	1.97 (1.03–3.77)	0.04	4.53 (2.06–9.97)	<0.001	7.98 (2.74–23.29)	<0.001
Phase of COVID-19 pandemic						
1st wave (April–August 2020)	1 [Reference]	NA	1 [Reference]	NA		
2nd wave (September 2020–February 2021)	1.20 (0.65–2.19)	0.56	1.37 (0.68–2.75)	0.38		
3rd wave (March–May 2021)	1.16 (0.61–2.20)	0.64	1.57 (0.74–3.31)	0.24		
Variant of concern						
Not a confirmed VOC ³	1 [Reference]	NA			1 [Reference]	NA
Confirmed VOC	0.81 (0.37–1.76)	0.59			0.63 (0.27–1.48)	0.29

421 Table 3. Logistic regression analysis of infants' characteristics associated with COVID-19 hospital admission

aOR = Adjusted odds ratio; OR = Odds ratio; VOC = variant of concern.

¹Multivariable analysis was conducted among 440 complete cases, and excludes 58 non-COVID-19-related hospitalizations.

²Multivariable analysis conducted among 268 complete cases reported from the Centre Hospitalier Universitaire Sainte-Justine, Hospital for Sick Children, or Montreal Children's Hospital and occurring on or after September 1, 2020. Excludes 25 patients hospitalized for reasons other than COVID-19. Given a smaller available sample size, VOC status was forced into the multivariable model and other covariates were selected on the basis of p-values until an events-per-variable ratio of 1:10 was reached to avoid overfitting.

³Cases occurring before December 26, 2020 (i.e. first case of confirmed Alpha in Canada) were assumed as 'not a confirmed VOC'. Cases with no VOC screening and occurring on or after December 26, 2020 (n=119) were also assumed as 'not a confirmed VOC'. Excluding the latter cases from the multivariable analysis did not meaningfully change the aOR (0.62; 95% CI 0.24–1.66).

REFERENCES

- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 7 Apr 2020;323(13):1239242.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 28 March 2020;395(10229):1054
 62.
- 3. Tostmann A, Bradley J, Bousema T, et al. Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020. Eurosurveillance. 23 avr 2020;25(16):2000508.
- Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically III
 Patients With COVID-19 in Washington State. JAMA. 28 Apr 2020;323(16):1612□4.
- Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 30 Apr 2020;382(18):1708 20.
- Bixler D. SARS-CoV-2–Associated Deaths Among Persons Aged 21 Years United States, February 12–July 31, 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020 [cited 2 feb 2021];69. Available from:

https://www.cdc.gov/mmwr/volumes/69/wr/mm6937e4.htm.

- Bellino S, Punzo O, Rota MC, et al. COVID-19 Disease Severity Risk Factors for Pediatric Patients in Italy. Pediatrics. oct 2020;146(4).
- Woodruff RC, Campbell AP, Taylor CA, et al. Risk Factors for Severe COVID-19 in Children. *Pediatrics*. 2021.

- Gale C, Quigley MA, Placzek A, et al. Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: a prospective national cohort study using active surveillance. The Lancet Child & Adolescent Health. 1 Feb 2021;5(2):113
 21.
- 10. Leung C. The younger the milder clinical course of COVID-19: Even in newborns?Pediatr Allergy Immunol. Feb 2021;32(2):358 62.
- Mithal LB, Machut KZ, Muller WJ, Kociolek LK. SARS-CoV-2 Infection in Infants Less than 90 Days Old. J Pediatr. sept 2020;224:150
 2.
- Panetta L, Proulx C, Drouin O, et al. Clinical Characteristics and Disease Severity Among Infants With SARS-CoV-2 Infection in Montreal, Quebec, Canada. JAMA Netw Open. 1 Dec 2020;3(12):e2030470.
- 13. Kitano T, Kitano M, Krueger C, et al. The differential impact of pediatric COVID-19 between high-income countries and low- and middle-income countries: A systematic review of fatality and ICU admission in children worldwide. *PLoS One*. 2021;16(1):e0246326.
- 14. CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek S, Gierke R, Hughes M, McNamara LA, et al. Coronavirus Disease 2019 in Children United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep. 10 Apr 2020;69(14):422 □ 6.
- van der Zalm MM, Lishman J, Verhagen LM, et al. Clinical experience with SARS CoV2 related illness in children hospital experience in Cape Town, South Africa. Clin Infect
 Dis. 10 nov 2020.
- National Collaborating Centre for Infectious Diseases. Updates on COVID-19 Variants of Concern. [Cited 2021 Sept 13]; Available from: <u>https://nccid.ca/covid-19-variants/</u>.

17. Moderna. Phase 2/3 study expected to enroll 6,750 healthy pediatric participants less than12 years of age. [Cited 2021 Sept 13]; Available from:

https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-

first-participants-dosed-phase-23-study-0.

- About the CPSP | Canadian Paediatric Surveillance Program [Internet]. [cited 28 may 2021]. Available from: <u>https://www.cpsp.cps.ca/about-apropos</u>.
- Number of Physicians by Province/Territory and Specialty, Canada, 2019 [Internet].
 Canadian Medical Association. [cited 28 may 2021]. Available from: https://www.cma.ca/number-physicians-provinceterritory-and-specialty-canada-2019, https://www.cma.ca/number-physicians-provinceterritory-and-specialty-canada-2019.
- COVID-19 | Canadian Paediatric Surveillance Program [Internet]. [cited 28 May 2021].
 Available from: <u>https://www.cpsp.cps.ca/surveillance/study-etude/covid-19/</u>.
- Public Health Agency of Canada. Coronavirus disease (COVID-19): Outbreak update [Internet]. aem. 2020 [cited 31 May 2021]. Available from: <u>https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection.html?topic=tilelink</u>.
- 22. Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis.* 2020;20(8):e192-e197.
- Pantell RH, Roberts KB, Adams WG, et al. Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old. *Pediatrics*. 2021;148(2).
- 24. Griffith GJ, Morris TT, Tudball MJ, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. *Nat Commun.* 2020;11(1):5749.

- 25. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. :15. .
- 26. Cui X, Zhao Z, Zhang T, et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). *J Med Virol*. 2021;93(2):1057-1069.
- 27. Hoang A, Chorath K, Moreira A, et al. COVID-19 in 7780 pediatric patients: A systematic review. *EClinicalMedicine*. 2020;24:100433.
- Drouin O, Hepburn CM, Farrar DS, et al. Characteristics of children admitted to hospital with acute SARS-CoV-2 infection in Canada in 2020. *CMAJ*. 2021;193(38):E1483-E1493.
- 29. Smith, C., Odd, D., Harwood, R. et al. Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med (2021). https://doi.org/10.1038/s41591-021-01578-1.
- 30. Sinaei R, Pezeshki S, Parvaresh S, Sinaei R. Why COVID-19 is less frequent and severe in children: a narrative review. *World J Pediatr*. 2021;17(1):10-20.
- Paret M, Lalani K, Hedari C, et al. SARS-CoV-2 Among Infants <90 Days of Age Admitted for Serious Bacterial Infection Evaluation. *Pediatrics*. 2021.
- 32. Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. *Clin Microbiol Rev.* 2010;23(1):74-98.
- Marodi L. Neonatal innate immunity to infectious agents. *Infect Immun*. 2006;74(4):1999-2006.

- Mehaffey JH, Arnold M, Huffstetler E, Mehaffey RL, Quillian H, Mehaffey JH.
 Successful vertical transmission of SARS-CoV-2 antibodies after maternal vaccination.
 Birth. 2021.
- Beharier O, Plitman Mayo R, Raz T, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. *J Clin Invest.* 2021;131(19).
- Trostle ME, Aguero-Rosenfeld ME, Roman AS, Lighter JL. High antibody levels in cord blood from pregnant women vaccinated against COVID-19. *Am J Obstet Gynecol MFM*. 2021:100481.
- COVID Data Tracker. Vaccinations Among Pregnant People.. [Cited 2021 Nov 2];
 Available from: https://covid.cdc.gov/covid-data-tracker/#vaccinations-pregnant-women.
- ICES [Internet]. ICES COVID-19 Dashboard. [cited 12 Dec 2021]. Available from: https://www.ices.on.ca/DAS/AHRQ/COVID-19-Dashboard.
- 39. Sagheb S, Lamsehchi A, Jafary M, Atef-Yekta R, Sadeghi K. Two seriously ill neonates born to mothers with COVID-19 pneumonia- a case report. *Ital J Pediatr*. 2020;46(1):137.
- 40. Kumar VHS, Prasath A, Blanco C, et al. Respiratory Failure in an Extremely Premature Neonate with COVID-19. *Children (Basel)*. 2021;8(6).
- 41. Ng DC, Chin L, Choo PPL, Paramasivam U. COVID-19 in a premature infant. *BMJ Case Rep.* 2021;14(5).
- 42. Piersigilli F, Carkeek K, Hocq C, et al. COVID-19 in a 26-week preterm neonate. *Lancet Child Adolesc Health*. 2020;4(6):476-478.

- Rivera-Hernandez P, Nair J, Islam S, Davidson L, Chang A, Elberson V. Coronavirus Disease 2019 in a Premature Infant: Vertical Transmission and Antibody Response or Lack Thereof. *AJP Rep.* 2020;10(3):e224-e227.
- 44. Brookman S, Cook J, Zucherman M, Broughton S, Harman K, Gupta A. Effect of the new SARS-CoV-2 variant B.1.1.7 on children and young people. *Lancet Child Adolesc Health*. 2021;5(4):e9-e10.
- 45. Public Health Ontario. Estimating the Prevalence and Growth of SARS-CoV-2 Variants in Ontario using Mutation Profiles. Enhanced Epidemiological Summary [Internet]. 2021 [cited 15 july 2021];69. Available from: <u>https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-prevalence-growth-voc-mutation-epi-summary.pdf?sc_lang=en</u>.